Oral Solid Dosage Contract Manufacturing Market (2026 - 2033)

Oral Solid Dosage Contract Manufacturing Market Summary

The global oral solid dosage contract manufacturing market size was valued at USD 10.2 billion in 2025 and is projected to grow from USD 11.1 billion in 2026 to USD 21.3 billion by 2033, growing at a CAGR of 9.7% from 2026 to 2033. North America dominated the global market with the largest revenue share of 38.7% in 2025. The market is experiencing growth driven by rising demand for outsourcing by pharmaceutical companies, expansion of generic drug market and patent expirations, continuous advancements in drug delivery technologies and increasing focus on supply chain resilience and localization.

Pharmaceutical and biopharmaceutical companies are outsourcing oral solid dosage (OSD) manufacturing to contract development and manufacturing organizations (CDMOs) in large numbers to reduce capital expenditure and operational complexity. In addition, developing in-house capabilities for formulation, scale-up, and commercial production requires significant investment in infrastructure, skilled labor, and regulatory compliance. By partnering with CDMOs, companies can focus on core competencies such as research, clinical development, and commercialization. For instance, in December 2025, Bora Pharmaceuticals and Corealis Pharma partnered to provide integrated oral solid dosage development and manufacturing services, combining early-stage expertise with commercial-scale capabilities to accelerate drug development and reduce outsourcing complexity. In addition, outsourcing also provides access to specialized technologies, flexible production capacity, and global regulatory expertise. This trend is particularly strong among small and mid-sized biotech firms that lack manufacturing capabilities, as well as large pharmaceutical companies seeking to optimize costs, enhance efficiency, and accelerate time-to-market for new drug products.

In addition, growing generic drug market, driven by patent expirations of blockbuster drugs, is boosting demand for OSD contract manufacturing. As patents expire, generic drug manufacturers aim to quickly develop and launch cost-effective alternatives to capture market share. This creates a need for rapid formulation development, scale-up, and high-volume production capabilities, which CDMOs are well-equipped to provide. In addition, increasing healthcare cost pressures and government initiatives to promote affordable medicines are accelerating generic drug adoption globally. CDMOs offer cost-efficient manufacturing solutions, regulatory support, and scalability, enabling generic companies to meet high demand while maintaining compliance and quality standards, thus fueling growth in the market.

Furthermore, continuous advancements in drug delivery technologies is one of the key driver OSD contract manufacturing market. According to a report of March 2026, increasing complexity of highly potent oral solid dosage (HPOSD) drugs accelerates the growing pipeline of potent, low-dosage, and specialized formulations that requires advanced containment systems, specialized facilities, and strict safety protocols. These manufacturing challenges, combined with evolving regulatory expectations and occupational safety requirements, make in-house production difficult for many pharmaceutical companies. As a result, companies are outsourcing to CDMOs in large numbers with high-containment infrastructure, technical expertise, and proven quality systems. In addition, the need for efficient tech transfer, scalability, and “right-first-time” manufacturing approaches is accelerating reliance on experienced partners.

Moreover, pharmaceutical companies are placing greater emphasis on building resilient and flexible supply chains, particularly after disruptions experienced during global crises. This has led to increased investment in regional manufacturing capabilities and partnerships with CDMOs to ensure consistent supply of oral solid dosage drugs. In addition, companies are adopting multi-site manufacturing strategies and nearshoring approaches to reduce dependency on single regions and mitigate risks related to logistics, geopolitics, and regulatory changes. CDMOs with global footprints and integrated service offerings are well-positioned to support these strategies. Their ability to provide comprehensive solutions, from development to commercial manufacturing across multiple regions, enhances supply chain agility and reliability, making them critical partners in the evolving pharmaceutical landscape.

Market Dynamics

The oral solid dosage contract manufacturing market is experiencing significant growth driven by shifting trends among pharmaceutical companies turning to outsourcing to achieve cost efficiency, flexibility in capacity, and faster time-to-market. Key trends contributing to the market are rising demand for complex formulations, such as modified-release drugs, high-potency products, and combination therapies, which require sophisticated manufacturing capabilities and containment measures. The adoption of continuous manufacturing processes, along with digitalization and quality-by-design approaches, is improving operational efficiency and ensuring regulatory compliance. Moreover, companies are diversifying their supply chains and implementing nearshoring strategies to mitigate geopolitical risks. While emerging markets are solidifying their manufacturing presence, established manufacturers are focusing on expanding capacity, forming strategic partnerships, and upgrading technology to maintain their competitive edge. Such factors are contributing to market growth.

Opportunity Analysis

The oral solid dosage contract manufacturing market presents strong growth opportunities attributed to increasing outsourcing by pharmaceutical and biopharmaceutical companies seeking cost efficiency, scalability, and faster time-to-market. Rising demand for complex formulations, including modified-release, fixed-dose combinations, and high-potency drugs, is creating opportunities for CDMOs with advanced technical capabilities. In addition, the growing pipeline of generic drugs and lifecycle management strategies for branded products are fueling demand for flexible and high-volume manufacturing solutions.

Furthermore, emerging markets offer significant expansion potential due to improving healthcare infrastructure, supportive government policies, and lower manufacturing costs, attracting global pharmaceutical companies. The growing adoption of digital technologies, automation, and data-driven platforms is further enhancing operational efficiency and enabling CDMOs to provide integrated, end-to-end services from development to commercialization. Moreover, rising focus on supply chain resilience and localization is encouraging investments in regional manufacturing facilities.

Impact of U.S. Tariffs on Oral Solid Dosage Contract Manufacturing Market

U.S. tariffs are significantly influencing the oral solid dosage contract manufacturing market by increasing input costs and transforming global supply chains. Tariffs on APIs, excipients, and components have raised production expenses, creating pricing pressure for CDMOs and OEMs. These measures are also driving supply chain diversification, with companies shifting manufacturing to tariff-efficient regions such as India, Europe, and Mexico. In addition, tariffs encourage domestic manufacturing investments, though high capital requirements limit rapid reshoring. Despite disruptions, the CDMO sector remains relatively resilient due to long-term contracts and pricing protections. Thus, tariffs are accelerating regionalization, cost optimization strategies, and strategic outsourcing decisions in the market. 

Technological Advancements

The oral solid dosage contract manufacturing market is witnessing significant technological advancements, particularly in modified-release drug delivery systems. Manufacturers are increasingly developing controlled- and sustained-release formulations to maintain consistent therapeutic levels, reduce dosing frequency, and improve patient adherence. In parallel, the shift toward personalized medicine is gaining momentum, with the use of artificial intelligence and predictive modeling enabling the design of patient-specific formulations that enhance treatment efficacy and precision. In addition, integration of digital health technologies into oral solid dosage forms is also emerging as a key trend, supporting improved patient monitoring, adherence tracking, and data collection for better clinical outcomes. In addition, the adoption of 3D printing technology is transforming manufacturing capabilities by enabling precise control over drug release profiles and facilitating the production of customized dosage forms with complex geometries.

Furthermore, the application of artificial intelligence and machine learning is streamlining drug development by optimizing formulation strategies, improving excipient selection, and enhancing bioavailability and solubility. These data-driven approaches reduce trial-and-error cycles, accelerate development timelines, and improve overall efficiency, collectively driving innovation and growth in the market.

Pricing Model Analysis

The oral solid dosage (OSD) contract manufacturing market utilizes diverse pricing models to balance cost efficiency, flexibility, and risk-sharing. Milestone-based pricing links payments to defined project stages such as development, validation, and commercialization, ensuring accountability and progress tracking. Value-based pricing is structured around actual production costs plus a margin, emphasizing transparency and aligning pricing with quality and performance outcomes. The fixed-fee model involves predetermined charges for specific services such as formulation, batch production, or validation, offering cost predictability for standardized or early-stage projects but limiting flexibility. In addition, the subscription or retainer model provides ongoing access to manufacturing capacity and technical expertise through recurring payments, supporting long-term partnerships and ensuring resource availability. These pricing approaches are often combined in hybrid structures, enabling companies to optimize costs, manage risks, and maintain operational efficiency across different stages of the product lifecycle in the OSD contract manufacturing market. 

Market Concentration & Characteristics

The oral solid dosage (OSD) contract manufacturing market is stable and is expected to accelerate growth over the estimated period. The market is characterized by technologies, regulatory considerations, and globalization & outsourcing of product processes to influence advantages and specialized capabilities.

The market has increasing focus on modified-release formulations, fixed-dose combinations, and high-potency drugs. Adoption of advanced technologies such as continuous manufacturing, AI-driven formulation, and 3D printing is improving efficiency and product quality. Innovation in excipients, coating technologies, and bioavailability enhancement is enabling development of complex oral therapies, supporting market growth and differentiation.

Regulatory frameworks significantly influence the OSD market, with strict compliance requirements under global GMP standards, data integrity norms, and validation protocols. Authorities such as FDA and EMA enforce rigorous quality and documentation processes, increasing operational complexity. While compliance raises costs, it also strengthens market entry barriers, driving pharmaceutical companies to rely on experienced CDMOs with established regulatory expertise.

M&A activity in the OSD contract manufacturing market is moderate to high, driven by the need to expand capabilities, geographic presence, and service portfolios. Companies are acquiring specialized CDMOs to enhance formulation expertise, increase production capacity, and access new markets. Consolidation is enabling end-to-end service offerings, improving competitiveness, and supporting long-term strategic growth in a fragmented market landscape.

Service expansion is a key trend, with CDMOs moving beyond basic manufacturing to offer integrated solutions including formulation development, clinical supply, scale-up, and commercial production. Many providers now support the full product lifecycle, including regulatory services and analytical testing. This end-to-end approach improves efficiency, reduces time-to-market, and strengthens long-term partnerships with pharmaceutical clients.

Regional expansion is accelerating as CDMOs establish facilities across North America, Europe, and Asia Pacific to improve supply chain resilience and meet global demand. Emerging markets are attracting investments due to cost advantages and growing pharmaceutical demand. Nearshoring and multi-region manufacturing strategies are increasingly adopted to reduce risks, enhance flexibility, and comply with regional regulatory requirements.

Analyst Perspective

The oral solid dosage contract manufacturing market is experiencing strong growth, driven by rising outsourcing from pharmaceutical and biopharmaceutical companies seeking cost efficiency, capacity flexibility, and faster time-to-market. In addition, the market demand is increasingly shaped by complex formulations, including modified-release tablets, high-potency APIs, and fixed-dose combinations, requiring advanced containment capabilities and specialized manufacturing infrastructure. Patent expirations and an expanding generics pipeline are further supporting large-scale, cost-optimized production requirements. The market is shifting toward end-to-end integrated CDMO partnerships, with sponsors consolidating vendors to reduce supply chain fragmentation and regulatory complexity. Besides, supply chain regionalization through nearshoring and dual-site manufacturing is gaining traction to mitigate geopolitical and logistics risks, further supporting the market growth. In addition, digital transformation encompassing AI-enabled process optimization, continuous manufacturing, and data-driven quality systems is enhancing operational efficiency and compliance. Thus, competitive dynamics are prompting CDMOs to expand global capacity and strengthen differentiated service offerings.

Product Type Insights

Based on product type, the tablets segment led the market with the largest revenue share of 32.4% in 2025 and is expected to grow at the fastest CAGR over the forecast period and is expected to grow at the fastest CAGR over the forecast period. The segment growth is attributed to its widespread use, accounting for nearly 70% of all medications. Tablets remain highly preferred due to their convenience, ease of administration, and cost-effectiveness. As demand continues to rise, this segment is expected to witness sustained growth. In addition, advancements in manufacturing technologies, such as continuous manufacturing and 3D printing, are enhancing production efficiency. For instance, the Technology House’s acquisition of the SLA 750 3D printer from 3D Systems is strengthening manufacturing capabilities through faster production, larger build capacity, and broader material options.

The capsules segment is expected to grow with the fastest CAGR during the forecast period, driven by growing advantages of capsules, such as ease of swallowing, faster disintegration, and absorption. These capsules disintegrate more quickly, rapidly releasing and absorbing medication. Moreover, technological advancements and the growing adoption of such technologies for expanding capsule-filling capabilities are expected to drive market growth. For instance, in December 2025, Bora Pharmaceuticals introduced high-potency liquid-filled hard capsule technology in Taiwan, expanding oral dosage capabilities, improving delivery of complex drugs, and accelerating development timelines to meet rising demand for advanced formulations. Thus, incorporating this innovative liquid capsule filling technology allows the company to extend assistance from early-phase to late-phase clinical trials, enhancing the capabilities for handling viscous formulations, and protecting oxygen-sensitive products through nitrogen overlay.

Mechanism Insights

Based on mechanism, the immediate release segment led the market with the largest revenue share in 2025. The segment is driven by rising need to overcome limitations of conventional delivery, including frequent dosing and variable drug levels. Some of the advancements such as stimuli-responsive and intelligent biomaterials, along with nano-drug delivery systems, enable targeted, sustained, and efficient drug release. These innovations improve patient compliance, therapeutic outcomes, and safety profiles. In addition, rising demand for chronic disease management and precision medicine is accelerating the adoption of controlled-release technologies across pharmaceutical development pipelines.

The immediate-release (IR) segment is expected to grow significantly during the forecast period.  The segment is driven by growing requirements for rapid therapeutic action, which makes it the most widely produced dosage form in the pharmaceutical market. Their relatively simple manufacturing process and lower production costs also contribute to their growing demand, particularly in emerging markets where cost-efficiency is critical. In addition, increasing demand for quick symptom relief and patient convenience supports its growth. Furthermore, advancements such as 3D printing are emerging as innovative approaches to manufacturing IR formulations with precision and flexibility. These technologies enhance production efficiency and customization, further strengthening the adoption of immediate-release dosage forms across various therapeutic applications.

End Use Insights

Based on end use, the large size companies segment led the market with the largest revenue share in 2025. The segment is driven by presence of robust manufacturing capabilities, global reach, and established client networks. The segment’s growth is supported by the need for operational efficiency, cost optimization, and a strategic focus on core areas such as drug discovery and commercialization. In addition, increasing regulatory complexity and rising demand for high-volume production of generics, branded generics, and specialty drugs are encouraging partnerships with contract manufacturers, enabling scalability, advanced technology access, and faster market entry for high-demand chronic therapies.

The medium and small-sized companies segment is expected to grow at the fastest CAGR during the forecast period. The growth is attributed to limited in-house manufacturing capabilities and high capital requirements for advanced facilities are driving these companies to outsource OSD production. In addition, the need for faster time-to-market, particularly for generics and specialty drugs, increases dependence on contract manufacturers. Furthermore, regulatory complexities, demand for scalable production, and access to specialized technologies such as modified-release formulations encourage outsourcing, enabling these companies to focus on R&D, marketing, and pipeline expansion.

Regional Insights

North America dominated the oral solid dosage contract manufacturing market with the largest revenue share of 38.7% in 2025. The market growth is driven by rising demand for generics, growing investments in R&D of new drugs by pharmaceutical companies, and increasing complexity of formulations. Some of the key players such as Catalent, Inc., Lonza Group, Recipharm AB, and Piramal Pharma Solutions dominate through scale, integrated services, and global reach. In addition, competition is intense with mid-sized CDMOs focusing on niche technologies. Furthermore, advancements in continuous manufacturing, high-potency API handling, and digital quality systems are enhancing efficiency.

U.S. Oral Solid Dosage Contract Manufacturing Market Trends

The oral solid dosage contract manufacturing market in the U.S. held the largest share in the North America region in 2025. For instance, in March 2026, the launch of Forma Life Sciences following BioSelective Capital Investments’ acquisition of BioDuro’s U.S. facilities highlights capacity expansion and investment momentum. In addition, technological advancements such as continuous manufacturing, advanced granulation, and digital quality systems enhance efficiency and compliance. The regulatory framework, governed by the U.S. Food and Drug Administration, emphasizes stringent GMP standards, data integrity, and quality assurance, ensuring high manufacturing reliability.

Canada oral solid dosage contract manufacturing market is expected to significantly grow over the estimated time period. The market growth is attributed to rising drug development complexity, cost optimization needs, and demand for integrated end-to-end CDMO services. Strategic collaborations enhance scalability from early development to commercialization, accelerating market growth. For instance, in December 2025, the alliance between Bora Pharmaceuticals and Corealis Pharma to deliver comprehensive oral solid dosage form development. The competitive landscape is moderately consolidated, with global CDMOs and specialized regional players competing on technological capabilities, regulatory compliance, and speed-to-market. Furthermore, Canada’s regulatory framework, governed by Health Canada, emphasizes stringent GMP standards, quality assurance, and compliance, ensuring safety, efficacy, and reliability in outsourced manufacturing operations.

Europe Oral Solid Dosage Contract Manufacturing Market Trends

Europe held a significant market share in 2025. The regional growth is driven by rising demand for generic drugs, growing outsourcing trends among pharmaceutical companies, and stringent regulatory requirements that favor specialized manufacturers. Further, technological advancements in formulation and manufacturing processes enhance outsourcing appeal. Countries such as Germany, Switzerland, and Ireland, with strong pharmaceutical infrastructures, play pivotal roles in supporting regional market growth.

Oral solid dosage contract manufacturing market in Germany is driven by advanced pharmaceutical infrastructure, strong demand for efficient drug development, and increasing outsourcing by pharmaceutical companies. Investments such as of September 2024, of Recipharm’s expansion of its GMP pilot-scale center in Zwickau enhance capabilities in blending, tableting, and capsule filling, enabling faster clinic-to-market timelines and cost-efficient production, thereby supporting market growth. In addition, the adoption of data-driven platforms for formulation and process optimization is improving development efficiency and product quality. The regulatory framework is highly stringent, governed by EU-GMP guidelines and national authorities, ensuring strict compliance, quality assurance, and validation standards, which further encourages outsourcing to experienced CDMOs.

The UK oral solid dosage contract manufacturing market is expected to grow significantly over the forecast period. The market growth is driven by increasing demand for generic drugs, a growing elderly population requiring chronic disease management, and pharmaceutical companies’ focus on cost optimization through outsourcing. In addition, stringent regulatory requirements encourage firms to partner with experienced CMOs for compliance support. Some of the advances in formulation technologies and a surge in small and mid-sized biotech firms lacking in-house manufacturing capabilities further boost the demand for specialized OSD contract manufacturing services across the country.

Asia Pacific Oral Solid Dosage Contract Manufacturing Market Trends

Asia Pacific oral solid dosage contract manufacturing industry is driven by cost advantages, a large and skilled workforce, strong availability of raw materials, and increasing outsourcing to emerging manufacturing hubs. In addition, investments in GMP-compliant facilities, pilot-scale capabilities, and data-driven platforms for faster drug development are enhancing regional competitiveness. The competitive landscape is fragmented, with regional and global CDMOs offering integrated development-to-commercialization services. Furthermore, the regulatory framework is evolving, with authorities strengthening GMP standards, streamlining approvals, and aligning with global guidelines, encouraging innovation, ensuring quality compliance, and attracting international pharmaceutical partnerships.

Oral solid dosage contract manufacturing market in China held a significant share in the market in 2025 and is driven by rising domestic demand, expanding pharmaceutical production capacity, and increasing collaborations between multinational companies and local CMOs. For instance, in March 2026, Eli Lilly expanded in Suzhou and Beijing, along with its USD 200 million partnership with Pharmaron, highlighting its efforts to strengthen supply chain resilience and meet growing demand for therapies like oral GLP-1 drugs. In addition, the regulatory framework is evolving under NMPA guidelines, with enhanced GMP standards, streamlined approvals, and stricter quality compliance, fostering innovation and attracting global outsourcing partnerships.

Oral solid dosage contract manufacturing market in Japan is expected to grow over the forecast period due to increasing demand for reliable medicine supply, high-quality standards, and capacity expansion by CDMOs. For instance, in March 2025, Adragos Pharma expanded its Kawagoe facility, in Japan targeting up to two billion tablets, to strengthen supply chain resilience and meet domestic demand. In addition, pharmaceutical companies are outsourcing manufacturing in large numbers to focus on R&D and to navigate stringent regulatory requirements more efficiently. The government's initiatives to promote the use of generics, alongside cost-containment measures in healthcare, are further encouraging partnerships with contract manufacturers.

Oral solid dosage contract manufacturing market in India is expected to experience significant growth at a significant CAGR during the forecast period. The country is emerging as one of the lucrative markets for oral solid dosage contract manufacturing across the globe. This can be attributed to low costs, the availability of industry experts, expansion of Indian contract manufacturers around the globe and the presence of WHO-cGMP-compliant facilities.

Latin America Oral Solid Dosage Contract Manufacturing Market Trends

The market growth is attributed to rising pharmaceutical demand due to a growing middle-class population and expanding healthcare access. Compared to North America and Europe, cost advantages make the region attractive for outsourcing. Governments are increasingly supporting local manufacturing through incentives and regulatory reforms, particularly in countries such as Brazil and Argentina. Multinational pharmaceutical companies are also partnering with regional contract manufacturers to meet local and export demands. The shift toward generic and over-the-counter (OTC) drug consumption, combined with the rising prevalence of chronic diseases, further boosts market opportunities.

The oral solid dosage contract manufacturing market in Brazil is expected to grow over the forecast period driven by a large domestic pharmaceutical sector, increasing demand for affordable generics, and supportive government policies enhancing local production. Brazil’s universal healthcare system (SUS) creates consistent demand for cost-effective medications, encouraging pharmaceutical companies to outsource manufacturing to optimize costs and expand capacity. Regulatory alignment with international standards, such as ANVISA’s improvements in GMP inspections, enhances the global competitiveness of Brazilian contract manufacturers.

Middle East and Africa Oral Solid Dosage Contract Manufacturing Market Trends

The MEA accounted for a significant revenue share in the global oral solid dosage contract manufacturing industry in 2025. The regional growth can be attributed to increasing healthcare demand, import substitution policies, and government-led localization initiatives supporting domestic pharmaceutical production. In addition, growing investments in GMP-compliant facilities and partnerships with international CDMOs are strengthening regional capacity. The competitive landscape remains moderately fragmented, with regional manufacturers and global entrants expanding footprints. The regulatory framework is evolving, with authorities enhancing GMP standards, centralized procurement systems, and quality compliance requirements to ensure safe, reliable, and locally manufactured medicines.

South Africa oral solid dosage contract manufacturing market is witnessing growth due to the increasing government focus on local pharmaceutical production, and centralized procurement systems that encourage domestic manufacturing partnerships. In addition, public health programs and expanding access to essential medicines are boosting demand for cost-effective, locally produced oral solid drugs. The regulatory framework is governed by SAHPRA, with evolving GMP standards and quality requirements aimed at strengthening compliance, improving supply security, and supporting the growth of reliable, locally aligned CDMO capabilities.

Oral solid dosage contract manufacturing market in Saudi Arabia is driven by strong government initiatives under Vision 2030, increasing localization efforts, and rising demand for essential medicines. For instance, in February 2026, Ashmore’s stake in Pharco KSA to develop a large-scale manufacturing facility in Al Madinah strengthened domestic production and supply security. The regulatory framework is governed by the Saudi Food and Drug Authority (SFDA), emphasizing stringent GMP compliance, quality standards, and local content requirements, encouraging partnerships with compliant contract manufacturers.

Key Oral Solid Dosage Contract Manufacturing Company Insights

Some oral solid dosage contract manufacturing companies are Boehringer Ingelheim International GmbH, Lonza, Catalent, Inc., Aenova Group, Jubilant Pharmova Limited, Patheon Pharma Services, Recipharm AB., Corden Pharma International, Piramal Pharma Solutions, Siegfried Holding AG, and AbbVie Contract Manufacturing, Next Pharma AB, among others. These key participants implement various strategic initiatives to strengthen their global market position. The prominent strategies companies adopt are acquisitions, collaborations, expansion, service launches, partnerships, and others to increase market presence & revenue and gain a competitive edge. For instance, in March 2026, LGM Pharma is investing USD 15 million across Texas and Colorado facilities to expand oral solid dosage, semi-solid, and R&D capabilities, strengthening domestic manufacturing capacity and supporting growing U.S.-based pharmaceutical demand.

Competitive Benchmarking

Recent Developments

• In March 2026, Forma Life Sciences launched a U.S.-based CDMO platform with two GMP facilities, offering integrated oral solid dosage development and commercial manufacturing, supporting clinical-to-commercial scale production with advanced formulation capabilities.

• In April 2025, Piramal Pharma Solutions launched a dedicated oral solid dosage suite in Pennsylvania to support fixed-dose combination production, enhancing manufacturing efficiency, scalability, and readiness for high-demand investigational therapies.

• In February 2025, Jabil acquired Pharmaceutics International, Inc., expanding its CDMO capabilities in oral solid dosage and drug delivery systems, strengthening its end-to-end development and commercial manufacturing offerings across multiple pharmaceutical segments.

Oral Solid Dosage Contract Manufacturing Market Report Scope

Global Oral Solid Dosage Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oral solid dosage contract manufacturing market based on product, mechanism, end use, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Tablets

  • Capsules

  • Powders

  • Granules

  • Others

• Mechanism Outlook (Revenue, USD Million, 2021 - 2033)

  • Immediate Release

  • Delayed Release

  • Controlled Release

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Large Size Companies

  • Medium & Small Size Companies

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Oman

    • Qatar

Research Methodology

Segment Definition 

 Estimation Model  

The OSD contract manufacturing market is assessed through a triangulated, multi-method framework that integrates bottom-up revenue build-up, top-down allocation, capacity utilization, and price-volume dynamics. This blended approach enhances estimation robustness by balancing supply-side constraints with demand-side outsourcing trends, thereby ensuring greater accuracy, consistency, and defensibility of market sizing outcomes in a complex and evolving pharmaceutical manufacturing landscape.

Delivered Customizations

This report has been delivered with the following In-depth customizations